AU
UK
CA
NZ
IND
US
Key Highlights
Esperion Therapeutics (NASDAQ:ESPR) jumped sharply after the developer of the LDL-cholesterol-lowering therapies Nexletol and Nexlizet (bempedoic acid and the bempedoic acid/ezetimibe fixed-dose combination) agreed to be taken private by Paris-based healthcare specialist Archimed in a transaction with an enterprise value of up to $1.1bn. …
A close look at how Merck is navigating Q1 2026 momentum, the looming Keytruda 2028 loss of exclusivity, and a reshaped pipeline anchored by Winrevair, Verona Pharma's Ohtuvayre, and the Daiichi Sankyo ADC alliance.Key HighlightsMerck reported Q1 2026Revenueof roughly $16.29 billion, up about 4.9% …
Please wait processing your request...